Grifols A : Grifols delivers the SRAAS disposal right at the year-end
>Agreement with Haier to sell 20% of Shanghai Raas for $1.8bn - Grifols has reached a strategic alliance and share purchase agreement with Haier for the sale of a 20% equity stake in SRAAS in exchange for RMB 12.5bn (c.$ 1.8bn), while retaining a stake in SRAAS of 6.58%. The completion of the transaction is subject to customary regulatory approvals and the buyer's confirmatory due diligence. The current commercial strategic collaboration arrangements between Grifols ...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.